OncLive TV

Alexander E. Perl, MD, assistant professor of medicine, University of Pennsylvania, discusses the evolving treatment landscape in acute myeloid leukemia.

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center and medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the potential of erlotinib (Tarceva) and bevacizumab (Avastin) in EGFR-mutant non–small cell lung cancer (NSCLC).

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in hepatocellular carcinoma (HCC).

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses reducing the cost of care in breast oncology.

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses findings with pembrolizumab (Keytruda) in non-muscle invasive bladder cancer.

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the importance of the ARROW trial in multiple myeloma.

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the EZH2 inhibitor tazemetostat in pediatric patients with INI1-negative tumors.

Terrill Jordan, president and CEO of Regional Cancer Care Associates, discusses RCCA’s efforts to further the fee-for-value model in oncology and make drugs more readily available to patients with cancer.

Ralph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.

Andrew Jennis, MD a hematologist/oncologist at Hackensack Meridian Health, who specializes in the diagnosis and treatment of digestive cancers, discusses the Centers for Medicare & Medicaid Services’ Oncology Care Model, a value model in which there is the opportunity for shared savings for both oncologists and CMS, so long as oncology care is administered in a cost-efficient manner.

Lani Alison, BCN, MS, HCQ, PCMH, CCE, vice president of clinical affairs at Regional Cancer Care Associates (RCCA), discusses future plans to develop an oft-overlooked area of oncology–survivorship/palliative care.

Kathleen Toomey, MD, who specializes in hematology and medical oncology and practices at the Steeplechase Cancer Center, discusses the results of the TAILORx trial, which reported that some patients with early-stage breast cancer can avoid chemotherapy.

Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.

Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial.

Seth Berk, MD, section chief of gastrointestinal hematology/oncology at Virtua Memorial Hospital, discusses the use of immunotherapy in colon cancer.

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center at Hackensack University Medical Center, discusses the affordability of cancer treatment breakthroughs such as chimeric antigen receptor T-cell therapy.

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination approaches garnering interest in endometrial cancer.

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the clinical utility of cell-free DNA (cfDNA) in guiding treatment decisions for patients with colorectal cancer (CRC).

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses the importance of long-term follow-up in pediatric patients with ependymoma.

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of CAR T-cell therapy in myeloma.

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events.

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the future of treatment for patients with ovarian cancer.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses duration of checkpoint inhibitor therapy in patients with melanoma.

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the potential for CAR T-cell therapy for the treatment of chronic lymphocytic leukemia.

Leslie J. Kohman, MD, FACS, Distinguished Service Professor of Surgery, Upstate Medical University, Upstate Cancer Center, discusses the results of the NELSON trial of screening in lung cancer.

Alexander E. Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of tepotinib and gefitinib (Iressa) in patients with MET-positive EGFR-mutant non–small cell lung cancer (NSCLC).

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the benefit of immunotherapy in the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the treatment of patients with HER2-driven gastric cancer.